

Development and Evaluation of a new Swiss Made SARS-CoV-2 antigen-detecting rapid test

Ducrest P.J.^{1*}

1 GaDia SA, Route de l'île aux bois 1A, 1870 Monthey, Switzerland

**Corresponding author: GaDia SA, route de l'île au bois 1A, 1870 Monthey, Switzerland, percevent.ducrest@gadia.net*

Key words: SARS-CoV-2, COVID-19, antigen, rapid diagnostic test, Lateral Flow immunoassay, Point-of Care Testing

Abstract

There is an urgent need in rapid diagnostic test (RDT) to detect antigen of SARS-CoV-2 to reduce the spread of COVID-19 outbreak. We have developed a rapid and simple point-of-care lateral flow immunoassay (LFIA) detecting nucleocapsid antigen of SARS-CoV-2 in 10 minutes. The aim of this study is to evaluate the diagnostic performance and analytical sensitivity of this RDT. RT-PCR positive nasopharyngeal swab samples (n=20) for SARS-CoV-2 and 40 negative control samples were studied. Analytical sensitivity was assessed using Gamma-irradiated SARS-CoV-2 and the limit of detection (LOD) was determined at 1.4×10^2 TCID₅₀/ml. Overall, RDT diagnostic sensitivity was 90% (95% confidence interval [95%CI]: 67-98%) and specificity 98% (95% CI: 85-100%). The sensitivity was 100% (95% CI: 75-100%) when using only samples with a RT-PCR Cycle threshold lower than 30. This antigen RDT displays a high diagnostic accuracy for SARS-CoV-2 antigen detection in high COVID-19 prevalence settings. Its use could be considered in the absence of routine RT-PCR facilities such in low-income countries.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 Introduction

45 The COVID-19 pandemic is a challenge for the population, healthcare systems and manufacturer of
46 medical devices. The easy and rapid detection of infected patient is crucial to shorten the spread of the
47 SARS-CoV-2. The actual gold standard for the diagnostic of COVID-19 is the reverse-transcription
48 Polymerase Chain Reaction (RT-PCR) but has certain inconveniences such as the time, laboratory and
49 equipment needed. Such analyses can difficultly be implemented in low-income countries where
50 laboratory or trained staff are missing [1-3].

51 Rapid antigen tests are lateral flow immunoassay with a visual (gold nanoparticles) or fluorescent
52 detection. Since the beginning of the COVID-19 outbreak, thousands of rapid tests have been listed on
53 the COVID-19 Testing pipeline of the Find Foundation (Geneva, Switzerland). Most of the test are
54 produced in Asia.

55 Recent studies highlighted a lower sensitivity compared to RT-PCR [4, 5]. However, the most common
56 rapid antigen test such as Panbio (Abbott), Standard Q (SD Biosensor, Roche Diagnostics) and BD
57 Veritor (Beckton & Dickinson) are the most studied and published tests. Based on a meta-analysis of
58 available performances data, the overall sensitivity for Panbio (Abbott) is 79% and the specificity is
59 99% (n=10936). For the Standard Q (SD Biosensor, Roche Diagnostics), the overall sensitivity is 85%
60 and specificity 99% (n=2892). Finally, the BD Veritor (Beckton & Dickinson) has an overall sensitivity
61 of 91% and a specificity of 99% (n=964) [6-9]. It has been noted that the sensitivity increases with high
62 viral load (RT-PCR Cycle threshold < 30). The World Health Organization (WHO) published a target
63 product profile with the minimal and desirable analytical and clinical performances (TPP WHO) [10].
64 The WHO recommended that an Ag-RDT test must have a sensitivity of at least 80% and a sensitivity
65 of at least 97%, based on the gold-standard RT-PCR test. The analytical performance must be at least
66 10^6 genomic copies/ml (CT 25-30).

67 A patient with a positive Ag-RDT result within 5 days after symptom onset can be considered to have a
68 SARS- CoV-2 infection, because these individuals are more likely to have high viral loads [11].
69 However, a negative result must be interpreted with caution due to reduced sensitivity with low viral
70 load and a confirmation test (RT-PCR) is recommended [10].

71

72 Here we have developed and evaluated a new rapid antigen-detecting test following the last
73 recommendation of the WHO. Both analytical performance and clinical performances have been
74 evaluated.

75

76

77

78

79

80

81

82 **Material & Methods**

83 **Study population and swab sample collection**

84 Anonymized leftovers of frozen Nasopharyngeal swab specimen, discharged in medium Tris EDTA 1X,
85 supplied by INO Specimens BioBank, ISB (Clermont-Ferrand, France), were used for the evaluation. A
86 total of 60 samples, including 40 negative and 20 positive samples were all evaluated with CE-IVD &
87 EUA-FDA reference RT-PCR Nucleic Acid Diagnostic Kit (Sansure Biotech Inc, Changsha, China) on
88 the QuantStudio 7 Pro Real-Time PCR Systems Instrument (Termofisher Scientific, Waltham, USA).
89 The positive samples were classified according to the Cycle Threshold (CT) for both probe *orf1 ab* and
90 *N gene*. The cut-off values for RT-PCR CT were < 39.00 for positive samples and > 42.00 for negative
91 samples.

92

93 **Inactivated SARS-CoV-2 and recombinant proteins**

94 SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Gamma-Irradiated and Heat-inactivated were
95 supplied by BEI Resources. Recombinant SARS-CoV-2 Nucleocapsid protein was supplied by
96 GenScript Biotech (Netherlands) B.V. (Leiden, NL). Tenfold dilution was prepared in the running buffer
97 of the test and evaluated in triplicates. The limit of detection is defined as the lowest concentration were
98 the signal intensity is equal or greater than 2 Rann score value (BBI, UK).

99

100 **Antigen Rapid test**

101 The Antigen-detecting rapid test COVIDia-Antigen was developed and manufactured in Switzerland by
102 GaDia SA (Monthey, Switzerland). This test detects the nucleocapsid antigen in nasopharyngeal and
103 throat swabs. The test has two pre-coated lines on a nitrocellulose membrane, one Control line (C) and
104 one Test line (T). The test line is composed of rabbit monoclonal anti-nucleocapsid antibody. The gold
105 nanoparticles (Nanocomposix, San Diego, USA) are coated with rabbit anti-Nucleocapsid antibodies.
106 The control line (C) is composed of a goat anti-rabbit antibody (Jackson ImmunoResearch Europe, Ely,
107 UK). When a positive sample flows through the test membrane, the anti-SARS-CoV-2 antibodies
108 present on the membrane (Test line) capture the antigen and form a colored conjugate complex on the
109 test line. The control line captures the excess of gold conjugate nanoparticles and forms a red line.

110

111 **Sample Testing**

112 The pouched test was opened immediately before use. To perform the test, 60 μ L of defrosted
113 Nasopharyngeal swab sample was diluted in 60 μ L of running buffer according to the manufacturer
114 instructions. Then, 100 μ L were added to the sample hole and the test was read after 15 minutes. For the
115 limit of detection using inactivated SARS-CoV-2, the sample was directly diluted in running buffer and
116 100 μ L were added to the test as describe above.

117

118 **Statistics**

119 Vassarstats online tool (www.vassarstats.net) was used to calculate sensitivity (SE), specificity (SP),
120 positive and negative predictive values (PPV, NPV), 95% confidence intervals, median, and
121 Interquartile range (IQR); while significance (p-values) was calculated using Mann-Whitney U test for
122 categorical variables. Statistical significance was defined as $p < 0.05$.

123

124

125

126

127 **Results**

128 **Baseline characteristics**

129 The baseline demographic characteristics of patients' samples were as follows: the 20 RT-PCR
130 confirmed COVID-19 samples from patients were older (median 63 years old, IQR 44-80.75) compared
131 to the healthy plasma samples patients (n=40) (median 51 years old, IQR 39-70.75; $p < 0.05$). The
132 proportion of females in COVID-19 cohort was 75% (n=15) and 43% (n=17) in negative control group.
133 The median CT value for *N gene* probe is 25.03 (IQR 20.1-30.6) and for *orf1 ab* probe is 26.8 (IQR
134 21.5-30.2).

135

136 **Specificity of Antigen RDT on negative control group**

137 Antigen RDT diagnostic specificity (percent negative agreement, PNA) against negative control group
138 (n=40) is shown in Table 1. Antigen RDT revealed concordant results in 39 of 40 samples. Only one
139 discordant result showed a low positive signal, while being negative (false-positive). These resulted in
140 an Antigen RDT specificity (SP) of 97.5% (95% CI: 85.3-99.9%).

141

142 **Sensitivity of Antigen RDT against RT-PCR confirmed COVID-19 samples**

143 Antigen RDT diagnostic sensitivity (percent positive agreement, PPA) against RT-PCR confirmed
144 samples (n=20) is shown in Table 1. Antigen RDT revealed concordant results in 18 of 20 samples.
145 Only 2 samples, with a CT value >30 were negative (false-negative). These results indicate an Antigen
146 RDT sensitivity (Se) of 90.0% (95% CI: 66.9-98.2%). When considering samples with a CT <30 , the
147 sensitivity is 100% (95% CI: 74.7-100%). The table 2 indicate the Sensitivity or PPA compared to CT
148 values of samples.

149

150

151

152

153
154
155

Table 1: Diagnostic performance of antigen RDT

		RT-PCR		
		Positive	Negative	Total
COVIDia-Antigen	Positive	18	1	19
	Negative	2	39	41
	Total	20	40	60
Sensitivity		90.0% (CI _{95%} : 66.9-98.2%)		
Specificity		97.5% (CI _{95%} : 85.3-99.9%)		
PPV		94.7% (CI _{95%} : 71.9-99.7%)		
NPV		95.1% (CI _{95%} : 82.2-99.2%)		


156
157
158

Table 2: Percent positive agreement of the antigen RDT at different RT-PCR CT values.

CT values	Percent positive agreement (CI95%)
<20	100% (46.3-100%)
20-25	100% (46.3-100%)
25-30	100% (46.3-100%)
<30	100% (74.7-100%)
>30	60.0% (17.0-92.7%)
overall	90.0% (66.9-98.2%)

159
160
161
162
163
164
165

The two false-negative samples have a CT value (N gene) of respectively 31.05 and 35.01 visible on red on the figure 1. The signal intensity was inversely proportional to the RT-PCR CT value. The smaller the CT value, the highest the signal intensity. Based on the regression done on the 20 positive samples (figure 1), R-squared was 0.82 and the LOD with a Rann value of 2 can be estimated at a RT-PCR CT value of 31.5.



166
167
168

Figure 1 : Test line intensity of the antigen RDT compared to the CT value of RT-PCR (N gene). Blue dots represent true-positive samples and red dots false-negative results

169 Analytical Sensitivity of Antigen RDT

170 The analytical sensitivity of the Rapid diagnostic test was evaluated using Gamma-irradiated SARS-
171 CoV-2 (Isolate USA-WA1/2020) from BEI Resources. The irradiated SARS-CoV-2 was diluted in
172 running buffer and tested with rapid test 5 times. The LOD was defined as a signal intensity of 2 Rann
173 score value on all 5 replicates. The table below (table 3) give the results of the LOD evaluation. The
174 LOD of the Rapid test was defined at 1.4×10^2 TCID₅₀/ml, corresponding to 7.9×10^4 genome
175 equivalent/ml.

176

177 **Table 3:** Limit of detection of the antigen RDT using Gamma-irradiated SARS-CoV-2

SARS-CoV-2 strain	Gamma-Irradiated SARS-CoV-2, Isolate USA-WA1/2020 [BEI Resource, ref. NR-52287, Lot. 70039067]					
Stock titer (TCID ₅₀ /ml)	2.8 x 10 ⁶					
Stock titer (genome equivalent/ml)	1.57 x 10 ⁹					
Dilution	1/10	1/100	1/1000	1/10000	1/20000	1/40000
Concentration in dilution (TCID ₅₀ /ml)	2.8 x 10 ⁵	2.8 x 10 ⁴	2.8 x 10 ³	2.8 x 10 ²	1.4 x 10²	7.0 x 10 ¹
Concentration in dilution (genome equivalent/ml)	1.6 x 10 ⁸	1.6 x 10 ⁷	1.6 x 10 ⁶	1.6 x 10 ⁵	7.9 x 10⁴	3.9 x 10 ⁴
Signal intensity (Rann)	10	6	4	3	2	1
Replicates	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	100% (5/5)	60% (3/5)

178

179

180

181 Discussion

182 The key finding of the present evaluation study, using an unmatched case-control study including 33.3%
183 of negative control samples, is that the diagnostic accuracy of antigen RDT on frozen nasopharyngeal
184 swabs when using RT-PCR as reference method, displayed a Percent positive agreement (Sensitivity)
185 of 90.0%, a SP of 97.5%, a PPV of 94.7% and a NPV of 95.1%. These results are considered as desirable
186 for the sensitivity and acceptable for the specificity according to the Target Product Profile of the WHO.

187

188 The two false-negative results obtained with this RDT had a RT-PCR CT value bigger than 30, such
189 samples have less viral load. The analytical sensitivity of this RDT was defined at 1.4×10^2 TCID₅₀/ml,
190 corresponding to 7.9×10^4 genomic copies/ml (Table 3). The analytical sensitivity based on RT-PCR
191 CT value, was also extrapolated using the 20 positive samples (figure 1) and was defined at a CT value
192 of 31.5. The TPP from WHO defined an analytical sensitivity of at least 30 cycle threshold (CT) values
193 [10]. A Point-of-Care (POC) test that can consistently detects the most infectious patients, with high
194 viral load of at least 10^6 genomic copies/ml, in order to interrupt transmission. This RDT fulfills the TPP
195 of the WHO in term of sensitivity and specificity. The diagnostic sensitivity is comparable to the SD
196 Biosensor and Abbott Panbio rapid antigen tests [7, 8].

197

198 Such performances indicate that this RDT could be fit for purpose in clinical settings where a high
199 prevalence of COVID-19 prevails, especially in situations where RT-PCR are not available or cannot
200 be reliably used. Diagnostic performances in low prevalence populations still needs to be determined
201 and larger populations need to be tested. In addition, it is clear that antigen assay for SARS-CoV-2 need
202 to be performed in the first week after symptoms onset [6, 12]. Finally, here we used frozen
203 nasopharyngeal swab specimens and the test was performed in a laboratory environment; we may expect
204 different results in real-life at patients' bed and using fresh nasopharyngeal swab.

205

206 In addition, the test provided clear results, without indeterminate or invalid results (no Control line).
207 There are several limitations to this study. First, we present here the results of a method evaluation study
208 and not a seroprevalence study. Therefore, the PPV obtained here (based on a 33.3% proportion of cases
209 defined as laboratory confirmed SARS-CoV-2 by RT-PCR) will probably be lower in a low prevalence
210 setting. Another limitation of this validation study lies in its limited sample size leading to broad 95%
211 confidence intervals, requiring confirmation of these data at a larger scale. Finally, our present
212 conclusions only apply to this RDT, and must not be applied to any other RDTs currently available.

213

214 In conclusion, this RDT is not meant to replace a SARS-CoV-2 RT-PCR but could be a reliable option
215 for quickly assessing the presence of SARS-CoV-2 antigen in moderate to high COVID-19 prevalence
216 settings and when high viral loads are expected, especially in situations where a rapid result is needed
217 or where RT-PCR is not available. Further investigations in low prevalence situations and using
218 capillary blood are necessary.

219

220

221 **Conflicts of Interest:**

222 PJD is the CEO of GaDia SA, the developer and manufacturer of this RDT.

223 This study was funded by GaDia SA, Switzerland.

224

225

226 **References**

- 227 1. Chaimayo, C., Kaewnaphan, B., Tanlieng, N. et al. Rapid SARS-CoV-2 antigen detection assay
228 in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand.
229 *Virology* 17, 177 (2020). <https://doi.org/10.1186/s12985-020-01452-5> Krüger
230 2. Colavita et al., COVID-19 Antigen Rapid Test as Screening Strategy at the Points-of-Entry:
231 Experience in Lazio Region, Central Italy, August-October 2020, medRxiv 2020.11.26.
232 20232728; doi: <https://doi.org/10.1101/2020.11.26.20232728>
233 3. Fitzpatrick et al. Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests, *The*
234 *Lancet*, Volume 397, Issue 10268, 2021
235 4. Haage et al., Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated
236 temperatures, medRxiv 2021.01.06.21249314; doi: [https://doi.org/10.1101/2021.01.](https://doi.org/10.1101/2021.01.06.21249314)
237 [06.21249314](https://doi.org/10.1101/2021.01.06.21249314)

- 238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
5. Linares et al., Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms, *Journal of Clinical Virology*, 133, 2020
 6. Hayer et al., Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: A systematic meta-analysis of available data as per November 20, 2020, medRxiv 2020.12.22.20248614; doi: <https://doi.org/10.1101/2020.12.22.20248614>
 7. Corman et al., Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests, medRxiv 2020.11.12.20230292; doi: <https://doi.org/10.1101/2020.11.12.20230292>
 8. Lindner et al. SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing, medRxiv 2021.01.06.20249009; doi: <https://doi.org/10.1101/2021.01.06.20249009>
 9. World Health Organization, Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0, 28 September,2020, Geneva, Switzerland
 10. Masia et al., Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age, *Open Forum Infectious Diseases*, 2021;, ofab059, <https://doi.org/10.1093/ofid/ofab059>
 11. Pekosz et al., Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. *Clin Infect Dis*. 2021 Jan 20:ciaa1706. doi: 10.1093/cid/ciaa1706. Epub ahead of print. PMID: 33479756.